Suven gets patents from Aripo, South Korea

Hyderabad: Suven Life Sciences has secured a product patent each from African Regional Intellectual Property Organisation (Aripo) and South Korea. These two patents are valid through 2033 and 2034, respectively, said the pharma company in its communique to BSE. The patents are pertaining to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

Suven Life CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively

The granted claims of the patents are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia, said Suven Life. Its stock closed lower by Rs10,10 or 4.50 per cent to Rs214.30 on BSE.